Human Immunoglobulin E specific for Quercus gambelii pollen allergens (IgE (anti-Quercus gambelii))

Human Immunoglobulin E (IgE) antibodies specific for Quercus gambelii (Gambel oak) pollen allergens are the primary mediators of seasonal allergic disease in regions where this oak species is prevalent (Source: NIH/PubMed). These antibodies are produced by B cells following sensitization to oak pollen proteins, most notably the major allergen Que a 1 (Source: WHO/IUIS Allergen Nomenclature). Upon re-exposure, the allergens cross-link the IgE molecules bound to high-affinity receptors (FcεRI) on the surface of mast cells and basophils, triggering the release of inflammatory mediators like histamine and leukotrienes (Source: StatPearls). This physiological cascade results in the clinical manifestations of hay fever, including sneezing, rhinorrhea, and potentially exacerbating allergic asthma. Therapeutic strategies involve the use of anti-IgE monoclonal antibodies like omalizumab to sequester circulating IgE or allergen-specific immunotherapy (AIT) to modify the underlying immune response and induce long-term tolerance (Source: AAAAI). Monitoring the levels of these specific IgE antibodies in the serum remains a cornerstone for the diagnosis and management of oak pollen-induced allergies.

Other names

Anti-Gambel oak IgEQuercus gambelii-specific IgEOak pollen-specific IgEAnti-Que a 1 IgE

Omalizumab acts as a monoclonal antibody that binds to the Cε3 domain of free circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (Source: PubChem). Allergen-specific immunotherapy (AIT) utilizes Quercus gambelii pollen extracts to induce immunological tolerance, shifting the immune profile from a Th2-dominated response to a Th1/Treg-mediated response, which decreases specific IgE production and increases protective IgG4 antibodies (Source: AAAAI).